Ethic Inc. Reduces Stock Holdings in Humana Inc. $HUM

Key Points

• Ethic Inc. has significantly reduced its holdings in Humana Inc. by 57.3%, selling nearly 5,000 shares to hold only 3,692 shares valued at $978,000.
• Other institutional investors have been active as well, with Cary Street Partners increasing their stake by 63.9%, while several new positions were established during the first quarter.
• Despite a miss in earnings per share, Humana's revenue grew 9.6% year-over-year, hitting $32.39 billion, with analysts forecasting this year's earnings to average $16.47 per share.

Ethic Inc. decreased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 57.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,692 shares of the insurance provider's stock after selling 4,949 shares during the quarter. Ethic Inc.'s holdings in Humana were worth $978,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC lifted its position in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares during the period. Riverview Trust Co purchased a new position in Humana during the first quarter valued at $34,000. Garde Capital Inc. purchased a new position in Humana during the first quarter valued at $36,000. Zions Bancorporation National Association UT purchased a new position in Humana during the first quarter valued at $37,000. Finally, Transce3nd LLC purchased a new position in Humana during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Performance

NYSE:HUM opened at $288.0310 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock's fifty day moving average is $244.92 and its 200 day moving average is $253.44. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The firm has a market capitalization of $34.64 billion, a PE ratio of 22.11, a PEG ratio of 1.69 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter in the previous year, the business earned $6.96 EPS. The business's revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analyst Weigh In

HUM has been the subject of several recent research reports. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Bank of America lowered their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Morgan Stanley lowered their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. Finally, Piper Sandler lowered their price target on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Seven research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and an average price target of $281.43.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.